Literature DB >> 6285071

Ferrokinetics after high-dose methotrexate therapy.

A Schalhorn, H Sauer, W Wilmanns, G Stupp-Poutot.   

Abstract

After high-dose methotrexate with doses ranging from 2-10 g/m2, ferrokinetics were performed in 11 patients with different tumors. Iron-III-citrate-59Fe was injected at methotrexate serum concentrations ranging between 2.7 x 10(-7) -1.3 x 10(-8) M. With MTX levels greater than or equal to 4.2 x 10(-8) M the plasma iron clearance was always retarded, and the plasma iron turnover was diminished in 5 of 6 patients with levels of 3.1-8.9 x 10(-8) M at the time of the injection. In all cases with MTX concentrations greater than or equal to 5 x 10(-8) M the 59Fe-utilization as the measure of effective erythropoiesis was reduced pathologically below normal range. These results show that the erythropoiesis resumes its normal extent even in case of normal methotrexate clearance only when the methotrexate serum concentrations have fallen down below 5 x 10(-8) and that erythropoiesis is more sensitive against methotrexate toxicity than the granulocytopoiesis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6285071     DOI: 10.1007/bf01746198

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  13 in total

Review 1.  Ferrokinetics in man.

Authors:  C A Finch; K Deubelbeiss; J D Cook; J W Eschbach; L A Harker; D D Funk; G Marsaglia; R S Hillman; S Slichter; J W Adamson; A Ganzoni; E R Biblett
Journal:  Medicine (Baltimore)       Date:  1970-01       Impact factor: 1.889

2.  Ferrokinetics: a biologic model for plasma iron exchange in man.

Authors:  J D Cook; G Marsaglia; J W Eschbach; D D Funk; C A Finch
Journal:  J Clin Invest       Date:  1970-02       Impact factor: 14.808

Review 3.  Methotrexate revisited.

Authors:  E Frei
Journal:  Med Pediatr Oncol       Date:  1976

4.  [Ferrokinetics: principles, results, indications (author's transl)].

Authors:  A Schalhorn; W Wilmanns
Journal:  Klin Wochenschr       Date:  1981-04-01

5.  Ferrokinetics and erythropoiesis in man: an evaluation of ferrokinetic measurements.

Authors:  C Ricketts; I Cavill; J A Napier; A Jacobs
Journal:  Br J Haematol       Date:  1977-01       Impact factor: 6.998

6.  Effect of high-dose methotrexate with citrovorum factor on human granulopoiesis.

Authors:  W Schremi; H P Lohrmann
Journal:  Cancer Res       Date:  1979-10       Impact factor: 12.701

7.  Weekly high-dose methotrexate-citrovorum factor in osteogenic sarcoma: pre-surgical treatment of primary tumor and of overt pulmonary metastases.

Authors:  N Jaffe; E Frei; D Traggis; H Watts
Journal:  Cancer       Date:  1977-01       Impact factor: 6.860

8.  Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery.

Authors:  G Rosen; R C Marcove; B Caparros; A Nirenberg; C Kosloff; A G Huvos
Journal:  Cancer       Date:  1979-06       Impact factor: 6.860

9.  [Detection of methotrexate in human serum. Comparison between an enzymatic and an enzyme-immunologic method].

Authors:  A Schalhorn; W Wilmanns
Journal:  Onkologie       Date:  1980-08

10.  [Radiational basis and practice of the citrovorum factor (Leucovorin) protection after high-dose methotrexate therapy. High-dose methotrexate/leucovorin].

Authors:  H Sauer; A Schalhorn
Journal:  Onkologie       Date:  1980-04
View more
  2 in total

1.  The influence of high-dose methotrexate therapy on serum iron.

Authors:  A Schalhorn; W Wilmanns; G E Koczorek
Journal:  Klin Wochenschr       Date:  1986-05-15

2.  Pharmacokinetics of erythrocyte methotrexate after high-dose methotrexate.

Authors:  A Schalhorn; H Sauer; W Wilmanns; G Stupp-Poutot
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.